Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study

Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study

Authors

  • Luigi Gargiulo Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
  • Luciano Ibba Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
  • Alessandra Narcisi Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
  • Silvia Giordano Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.
  • Carlo A. Maronese Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Fabrizio Martora Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Federica Repetto Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.
  • Giovanni Paolino Unit of Dermatology, IRCCS Ospedale San Raffaele, Milan, Italy. Vita-Salute University, Milan, Italy
  • Anna Balato Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
  • Martina Burlando Department of Dermatology, Dipartimento di Scienze della Salute (DISSAL), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Paolo Dapavo Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.
  • Valentina Dini Dermatology Unit, Department of Clinical and Experimental Medicine Ospedale Santa Chiara, Pisa, Italy.
  • Claudio Guarneri Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Unit of Dermatology, University of Messina, AOU Policlinico G. Martino, Messina, Italy.
  • Angelo V. Marzano Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 5Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Santo R. Mercuri Unit of Dermatology, IRCCS Ospedale San Raffaele, Milan, Italy. Vita-Salute University, Milan, Italy
  • Antonio Costanzo Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
  • Mario Valenti Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

Keywords:

Anti-IL-17, Anti-IL-23, Hidradenitis suppurativa, Psoriasis

Abstract

Introduction: Psoriasis and hidradenitis suppurativa (HS) are chronic inflammatory diseases with significant overlap in their immunologic pathways, which involve cytokines such as tumor necrosis factor-alfa, interleukin (IL)-17, and IL-23. Current treatment options for HS are limited, as only adalimumab and secukinumab are approved for severe cases. Given the overlapping pathogenetic features between HS and psoriasis, anti-IL-17 and anti-IL-23 drugs could represent valuable treatments for the management of HS.

Objectives: We sought to evaluate the effectiveness and safety of anti-IL-17 and anti-IL-23 drugs in patients with HS and concomitant moderate-to-severe plaque psoriasis.

Methods: We conducted a multicenter retrospective study in 11 Italian Dermatology Units. The effectiveness of the drugs was evaluated by assessing the percentage of patients achieving HS Clinical Response (HiSCR) each week.

Results: We enrolled 41 patients with at least 16 weeks of follow-up, with 17 of them completing 52 weeks of treatment. The most commonly prescribed anti-IL drug was secukinumab (27 patients), followed by ixekizumab (5) and guselkumab (5). The HiSCR was achieved by 39%, 74.3%, and 77.8% of patients after 16, 32, and 52 weeks, respectively. No severe adverse events (AEs) or AEs leading to discontinuation were observed during the study. The most common AE was nasopharyngitis (4 patients).

Conclusion: In this real-world study, we highlight the effectiveness of anti-IL-23 and anti-IL-17 drugs in the treatment of concomitant plaque psoriasis and severe HS. Longer and larger studies are needed to further evaluate the long-term effectiveness and safety of these treatments in patients affected by HS.

References

Bukvić Mokos Z, Markota Čagalj A, Marinović B. Epidemiology of hidradenitis suppurativa. Clin Dermatol. 2023;41(5):564-575. DOI:10.1016/j.clindermatol.2023.08.020

Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133(6):1506-1511. DOI:10.1038/jid.2012.472.

Navrazhina K, Renert-Yuval Y, Khattri S, et al. Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativa. J Am Acad Dermatol. Published online December 3, 2023. DOI:10.1016/j.jaad.2023.11.048.

Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. Published online December 22, 2023. DOI:10.1080/1744666X.2023.2298356.

European Medicines Agency. Cosentyx (secukinumab): summary of product characteristics. 2015 [cited 2023 December 28]. https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx

Kridin K, Shani M, Schonmann Y, et al. Psoriasis and hidradenitis suppurativa: A large-scale population-based study. J Am Acad Dermatol. 2023;88(5):e231-e236. DOI:10.1016/j.jaad.2018.11.036.

Macca L, Li Pomi F, Ingrasciotta Y, Morrone P, Trifirò G, Guarneri C. Hidradenitis suppurativa and psoriasis: the odd couple. Front Med (Lausanne). 2023;10:1208817. Published 2023 Jul 7. DOI:10.3389/fmed.2023.1208817.

Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747-761. DOI:10.1016/S0140-6736(23)00022-3.

Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504-2519. DOI:10.1016/S0140-6736(24)00101-6.

Kimball AB, Prens EP, Passeron T, et al. Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial. Dermatol Ther (Heidelb). 2023;13(5):1099-1111. DOI:10.1007/s13555-023-00913-3.

Kimball AB, Podda M, Alavi A, et al. Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study. J Eur Acad Dermatol Venereol. 2023;37(10):2098-2108. DOI:10.1111/jdv.19252.

Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157(Suppl. 1 to No. 1):1-78. DOI:10.23736/S2784-8671.21.07132-2.

European Medicines Agency. Tremfya (guselkumab): summary of product characteristics. 2017 [cited 2023 December 28]. https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya

European Medicines Agency. Skyrizi (risankizumab): summary of product characteristics. 2019 [cited 2023 December 28]. https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi

European Medicines Agency. Kyntheum (brodalumab): summary of product characteristics. 2017 [cited 2023 December 28]. https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum

European Medicines Agency. Bimzelx (bimekizumab): summary of product characteristics. 2021 [cited 2023 December 28]. https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx

Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989-994. DOI:10.1111/jdv.13216.

Tzellos T, van Straalen KR, Kyrgidis A, et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37(2):395-401. DOI:10.1111/jdv.18632.

Malvaso D, Calabrese L, Chiricozzi A, et al. IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa. Pharmaceutics. 2023;15(10):2450. Published 2023 Oct 11. DOI:10.3390/pharmaceutics15102450.

Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021;35(7):e441-e442. DOI:10.1111/jdv.17178.

Fernandez-Crehuet P, Haselgruber S, Padial-Gomez A et al. Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study. Dermatol Ther (Heidelb). 2023 Apr;13(4):1029-1038. DOI: 10.1007/s13555-023-00906-2.

European Medicines Agency. Cosentyx (secukinumab): summary of product characteristics. 2014 [cited 2023 December 28]. https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx

Esme P, Botsali A, Akoglu G, Caliskan E. An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series. Skin Appendage Disord. 2022;8(4):342-345. DOI:10.1159/000521860.

Kearney N, Hughes R, Kirby B. Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic. Clin Exp Dermatol. 2023;48(7):790-792. DOI:10.1093/ced/llad130.

Navrazhina K, Frew JW, Grand D et al. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. Br J Dermatol. 2022 Aug;187(2):223-233. DOI: 10.1111/bjd.21060.

Frew JW, Grand D, Navrazhina K, Garcet S, Krueger JG. Assessing the responsiveness of sonographic biomarkers to Brodalumab therapy in Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e884-e887.

Glatt S, Jemec GBE, Forman S, et al. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial. JAMA Dermatol.2021;157(11):1279–1288. DOI:10.1001/jamadermatol.2021.2905.

Kok Y, Nicolopoulos J, Dolianitis C. Tildrakizumab as a potential long-term therapeutic agent for severe Hidradenitis Suppurativa: A 15 months experience of an Australian institution. Australas J Dermatol. 2021;62(2):e313-e316. DOI:10.1111/ajd.13559.

Koszegi B, Wilson A, Stone C, Satgé F, Cowan TL, Murrell DF. Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience. Clin Exp Dermatol. 2023;48(11):1266-1269. DOI:10.1093/ced/llad215.

Repetto F, Burzi L, Ribero S, Quaglino P, Dapavo P. Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series. Acta Derm Venereol. 2022;102:adv00780. Published 2022 Sep 28. DOI:10.2340/actadv.v102.2926.

Kimball AB, Podda M, Alavi A, et al. Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study. J Eur Acad Dermatol Venereol. 2023;37(10):2098-2108. DOI:10.1111/jdv.19252.

Dudink K, Bouwman K, Chen Y, et al. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study. Br J Dermatol. 2023;188(5):601-609. DOI:10.1093/bjd/ljad010.

Rivera-Díaz R, Pozo T, Alfageme F, et al. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study. [Artículo traducido] Efectividad de guselkumab en pacientes con hidradenitis supurativa en condiciones de práctica clínica: estudio retrospectivo y multicéntrico en España. Actas Dermosifiliogr. 2023;114(9):T755-T762. DOI:10.1016/j.ad.2023.06.018.

Martora F, Scalvenzi M, Battista T, et al. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data. Clin Cosmet Investig Dermatol. 2023;16:2525-2536. Published 2023 Sep 18. DOI:10.2147/CCID.S418748.

Downloads

Published

2024-10-30

How to Cite

1.
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study. Dermatol Pract Concept [Internet]. 2024 Oct. 30 [cited 2024 Dec. 6];14(4):e2024250. Available from: https://dpcj.org/index.php/dpc/article/view/4503

Share